QNCX (Quince Therapeutics) Tax Rate % : -0.06% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Quince Therapeutics's Tax Expense for the three months ended in Dec. 2024 was $0.01 Mil. Quince Therapeutics's Pre-Tax Income for the three months ended in Dec. 2024 was $-12.45 Mil. Therefore, Quince Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 was -0.06%.

Quince Therapeutics Tax Rate % Historical Data

The historical data trend for Quince Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics Tax Rate % Chart

Quince Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Rate %

Get a 7-Day Free Trial

0.55

0.62

-0.15

Quince Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Rate %	Get a 7-Day Free Trial															-0.58	-0.28	-0.13	-0.24	-0.06

Quince Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Quince Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2024 )	/	Pre-Tax Income (A: Dec. 2024 )
	=	0.087	/	-56.741
	=	-0.15 %

Quince Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %	=	Tax Expense (Q: Dec. 2024 )	/	Pre-Tax Income (Q: Dec. 2024 )
	=	0.007	/	-12.451
	=	-0.06 %

Quince Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Quince Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080

Website

https://www.quincetx.com

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Executives

Dirk Thye	director, officer: Chief Executive Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah	officer: Chief Business Officer	269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Charles S. Ryan	officer: President	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
David Lamond	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer	officer: Chief Scientific Officer	601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Margaret Mcloughlin	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon	officer: Chief Accounting Officer	C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray	director	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell	officer: Chief Legal & Adm. Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Philip S Low	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Karen L. Smith	officer: Chief Medical Officer	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy	director, officer: Chief Scientific Officer	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe	officer: Chief Financial Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258